Adagene (ADAG) vs Immunic (IMUX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Immunic (IMUX) has outperformed Adagene (ADAG) over the past year, gaining 1.9% versus a loss of 2.2%. Over five years, ADAG leads with a -79.7% price change compared with -91.9% for IMUX. Adagene is the larger company by market cap ($118.2 million vs $111.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | IMUX |
|---|---|---|
| Share price | $1.76 | $6.99 |
| Market cap | $118.17M | $111.01M |
| 1-day change | -12.44% | -5.41% |
| YTD return | -6.88% | +30.90% |
| 1-year return | -2.22% | +1.90% |
| 5-year return | -79.75% | -91.88% |
| EPS (TTM) | $-0.37 | $-3.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.67M | — |
| Revenue growth (YoY) | +7332.76% | — |
| Net income (latest FY) | $-17.61M | $-97.17M |
| Operating margin | -279.48% | — |
| Net margin | -229.56% | — |
| 52-week high | $4.85 | $17.43 |
| 52-week low | $1.27 | $5.06 |
| Distance from 52-week high | -63.71% | -59.90% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +463.07% | +508.73% |
| Average volume | 348.81K | 343.44K |
| Shares outstanding | 67.14M | 15.88M |
| Employees | 128 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Immunic
IMUX stock →Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
ADAG vs IMUX FAQ
Which is bigger, Adagene or Immunic?
Adagene (ADAG) is larger, with a market capitalization of $118.17M compared with $111.01M for Immunic (IMUX).
Which stock has performed better over the past year, ADAG or IMUX?
IMUX returned +1.90% over the past 12 months, compared with -2.22% for ADAG (price return, excluding dividends). Past performance does not predict future results.
Are Adagene and Immunic in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.